SCOLR and Dr. Reza Fassihi to Present Seven Drug Delivery Technology Innovations at AAPS Annual Meeting and Exposition, November 10-14, 2002, Toronto, Canada
REDMOND, WA., AUG. 13, 2002 —SCOLR, Inc. (OTC BB: SCLL) and Dr. Reza Fassihi, Professor of Biopharmaceutics and Industrial Pharmacy, Temple University, School of Pharmacy, jointly announced today that they will be presenting a total of seven CDTTM research papers at the 2002 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting to be held November 10 – 14, 2002 in Toronto, Canada www.aapspharmaceutica.com/annualmeeting/). The innovations to be presented are the result of the close working relationship and collaboration between SCOLR and Dr. Fassihi.
SCOLR will make the following presentations at the convention:
- “Modified Design of a Monolithic Oral Controlled-Release Delivery Formulation for Novasoy® Soy Isoflavone Concentrate,”
- “Novel Design of a Robust and Rugged Oral Monolithic Controlled Release Delivery System for Tramadol Hydrochloride,”
- “In Vivo-In Vitro Correlation (IVIVC) Of A Novel Monolithic Controlled Release Dosage Form,”
- “Novel Design of a Monolithic Oral Controlled-Release Delivery Formulation for Probiotic Organisms.”
Dr. Fassihi will make the following presentations to attendees:
- “A Novel In-Situ Solubilization For A ‘Dissolution Rate Limited’ Drug Within The Hydrophilic Matrix For Controlled Release Delivery: Ondansetron Hydrochloride,”
- “Design and Development Of A Controlled Release Formulation for ‘Dissolution-Rate Limited’ Dimenhydrinate Via In-Situ Interactions Of Charged Substances And Polymers,”
- “In-Situ Solubilization of Class II Drugs During The Hydrosol-Gelation Phase In The Presence of Amphoteric Amino Acids, Polysaccharides, and Polymers: A Novel Approach In Controlled Release Drug Delivery.”
As an emerging developer in controlled release technologies via its patented CDTTM platform, SCOLR welcomes the opportunity to engage the pharmaceutical scientific community with discussions of its patented, advanced delivery technologies. In addition, SCOLR will be exhibiting at the AAPS show in booths # 441-443.
Stephen J. Turner, Director of Product Development, said that, “The innovations and subsequent product opportunities that have resulted from the continued development of CDTTM technology - applications are truly exciting. The acceptance of the CDTTM research work at AAPS, which is regarded as one of the best scientific/pharmaceutical forums, is highly valued, and further demonstrates the sound scientific principles and recognition of our technologies.”
Dr. Fassihi, innovator of the CDT™ technology commented that, “The self-correcting controlled-release technology platform is remarkable from a proprietary point of view due to broad patent position and formulation uniqueness which makes it robust, scalable, and the fact that production requires standard tableting machines. The new aspect in the CDT portfolio is the extension of the technology providing potential for in-situ solubilization via ‘salt-in’ phenomena for either insoluble drugs or dissolution rate limited drugs. Three of the papers to be presented at the AAPS meeting will focus into this sophisticated innovation where a significant growth potential exists. Several other experimental drug delivery systems in the portfolio show exciting signs including multiple release kinetics for multiple drug delivery with specific trigger mechanisms.”
On July 2, 2002, shareholders approved the change of the Company’s name to SCOLR, Inc. (pronounced scholar - an acronym for Self Correcting Oral Linear Release) from Nutraceutix, Inc. in order to better reflect the Company’s transition to the drug delivery industry. Based in Redmond, Washington, SCOLR, Inc. is a biopharmaceutical company leveraging specialized knowledge, proprietary and patented products and technologies, such as the patented CDTTM platform, to introduce distinctive and novel OTC products, prescription drugs and dietary supplements. SCOLR currently operates in two business segments – drug delivery and a specialty ingredient business based on probiotics. Its CDTTM drug delivery platform provides distinctive products with tangible benefits for the consumer and competitive and commercial advantages for licensees. Established partnerships with pharmaceutical, OTC and natural products industry companies enable SCOLR to co-develop new products and to add value and protection to existing product franchises. For more information on SCOLR, please call 1.800.548.3222 or visit http://www.nutraceutix.com/delivery/ or email [email protected]
For more information on AAPS and its Annual Meeting and Exposition in Toronto, Canada, please visit http://www.aapspharmaceutica.com.
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 37A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties, including activities; events or developments that the company expects, believes or anticipates will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the Company's ability to continue to successfully market and provide its products and services and maintain their effectiveness, the continuation of the arrangements with the Company's product development partners, the ability of the Company to meet its financial projections, and general economic conditions. Such statements are subject to a number of assumptions, risks and uncertainties. Such forward-looking statements are subject to other risks and uncertainties, which are detailed in the Company's filings with the Securities and Exchange Commission. Readers are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements whether as a result of new information or otherwise.